Leader in the development of mobile, affordable, point-of-care diagnostics, Nanomix Corporation (OTCMKTS:NNMX) on September 2, 2022, announced an agreement with Mobility Health. The agreement will entail the Mobility Health plan and Nanomix to collaborate in the development of Lab Developed Test. The test can be deployed in a fully mobile lab to assess levels of circulating antibodies to COVID-19.
Trading Data
On Friday, NNMX stock ended flat at $0.2394 with more than 4.39K shares, compared to its average volume of 1.90K shares. The stock moved within a range of $0.2394 – 0.2394 after opening trade at $0.4000.
Nanomix Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies
The firm is planning to supply product elements as well as Mobility Health plans for finishing the development and validation of the test.
Mobility Health founder and CEO, Sandra Gunselman said that Nanomix’s affordable and point-of-care technology will be harnessed to give patients an accurate status of protection against COVID-19. Gunselman added that it would enable them to make informed decisions in consultation with their medical providers. The CEO further stated that the offering fits well with the mobile laboratory platform, even as it advances the mission of providing innovative products against COVID-19 and other infectious diseases.
Dr. Thomas Schlumpberger, Nanomix CEO said that they share Mobility Health’s mission of transforming community healthcare through higher accessibility to healthcare testing and services. The CEO also said that the firm believes that the eLab system is an ideal mobile platform for providing quick testing of COVID-19 antibodies and other future indications.
The Nanōmix eLab system is a hand-held immunoassay and chemistry diagnostic system made for the needs of rapid point-of-care testing.
Key Quote
Dr. Thomas Schlumpberger, Nanomix CEO, said, “We share Mobility Health’s mission to transform community healthcare through increased accessibility to healthcare testing and services. We believe our eLab system is the ideal mobile platform to provide rapid testing of COVID-19 antibodies, as well as many other future indications.”
